What it is
PT-141 (bremelanotide) is a centrally acting melanocortin receptor agonist with a licensed human indication for hypoactive sexual desire disorder. It works through the brain rather than the peripheral vascular pathway.
Evidence boundary
Human evidence and a licensed indication exist. Keep the interpretation close to the labeled PRN use case.
Trial evidence
- PMID 36242769 — An evaluation of bremelanotide injection for the treatment of hypoactive sexual desire disorder.
- PMID 38767282 — Pharmacotherapy of Hypoactive Sexual Desire Disorder in Premenopausal Women.
- PMID 41419078 — Strategies for Treating Sexual Health Concerns After Breast and Gynecologic Cancer.
Preparation and measurement
Reconstitution: 10 mg vial + 2 mL BAC = 5 mg/mL.
Concentration matches.
Reference schedule
| Phase | Dose | Draw / measure | Frequency | Weekly total |
|---|---|---|---|---|
| Initial tolerance exposure | 500 mcg | 10 U (0.1 mL) | Single PRN dose | Not fixed |
| Typical PRN range | 1–1.75 mg | 20–35 U (0.2–0.35 mL) | As needed; no more than once per 24 hours | Not fixed |
Initial tolerance exposure
- Dose
- 500 mcg
- Draw / measure
- 10 U (0.1 mL)
- Frequency
- Single PRN dose
- Weekly total
- Not fixed
Typical PRN range
- Dose
- 1–1.75 mg
- Draw / measure
- 20–35 U (0.2–0.35 mL)
- Frequency
- As needed; no more than once per 24 hours
- Weekly total
- Not fixed
Weekly totals do not apply here. This is on-demand use, not a daily schedule.
Titration rules
- This is an on-demand protocol, not a daily escalation.
- Start with the lower single dose before moving up.
- Do not exceed one administration in 24 hours.
- Keep the lowest effective PRN dose.
Cycle length and breaks
Use is PRN and assessed after each dose.
What to monitor
- Desired sexual-response effect
- Nausea, flushing, headache
- Transient hypotension
Practical rules
- Inject 30–45 minutes before the desired effect.
- Keep a firm 24-hour minimum between doses.
- Consider an antiemetic if nausea is a problem.
- Rotate sites if dosing sub-Q.